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time horizon and resources usage from a previous cost-effectiveness study for
medications used to treat hepatic encephalopathy from the Mexican Institute of
Social Security (IMSS) perspective and to complement it with a budget impact
analysis. METHODS: CE analysis of treatments used for acute HE, based in a deci-
sion tree model, and considering a horizon of 10 days. Alternatives available at the
IMSS are: lactulose, L-ornithine L-aspartate (LOLA), neomycin and alpha (a)poly-
morph rifaximin (the new alternative). Percentage of patients with improvement in
signs and symptoms of HE was the effectiveness measure and s based on available
published studies(Huang 2007 and Qian 2009). Only direct medical costs were con-
sidered and obtained from IMSS. Univariated sensitivity analysis, using pricing
discounts and effectiveness were performed and budget impact simulations were
developed. RESULTS: LOLA US$4024, lactulose US$4032, neomycin US$4060 and
rifaximin US $4039 final costs. In relation to effectiveness, the percentage of pa-
tients who presented improved signs and symptoms for each alternative is as
follows: lactulose and LOLA 55%, neomycin 64% and rifixamin 90%. Cost effective-
ness ratios are: lactulose US$7331, LOLA $7316, neomycin US$6344 and rifixamin
US$4488. The incremental cost effectiveness analysis indicates that LOLA and neo-
mycin are surpassed by lactulose and rifaximin, which are located on the efficiency
line. For the sensitivity analysis with one hospitalization day reduced due to the
improved efficacy, rifaximin was the dominating alternative. If lactulose and neo-
mycin are substituted by rifaximin in the estimated population(6,194 to 21,680
potential range of patients with HE in the Mexican Health System), the budget
impact shows savings equivalent to 77.74 y 72.36%, respectively. CONCLUSIONS:
Alpha (a) polymorph rifaximin is a highly cost effective alternative for treating
acute HE from an institutional perspective in México.
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OBJECTIVES: To estimate the budgetary impact of RRMS treatment from the per-
spective of the NHS in Spain (valued Euros-2011), in order to determine which
treatment is most efficient from the payer’s perspective.METHODS: IMS sales data
for multiple sclerosis drugs were used to estimate the total number of patients
treated with each of the drugs used during 2011. The number of patients receiving
treatment was calculated from the yearly cost of each treatment per patient (ex-
factory price excluding VAT) because IMS presents total sales expressed as ex-
factory price, which means that the yearly cost of the drug expressed as ex-factory
price must be used to estimate the number of patients from the IMS sales data.
Although there are clear differences in the effectiveness of the treatments used,
these differences do not always explain differences in prices (higher incremental
costs). RESULTS: Total expenditure in Spain in 2011 was €259 million. Among the
patients, 47% were treated with interferon beta-1a, 27% with interferon beta-1b,
16% with glatiramer acetate and 10% with natalizumab. In the unlikely event that
all patients had used interferon beta-1a in Spain, total expenditure would have
been between -10% and 6.3%, depending on the drug used. If interferon beta 1b
had been used by all patients, the total savings in Spain during 2011 would have
been over 12.5%. Nonetheless, the greatest savings (15% of total expenditure)
would have been achieved if all patients had been treated with glatiramer acetate.
CONCLUSIONS: Despite the limitations of the study (only direct drug costs were
considered and the number of patients receiving treatment was extrapolated) this
methodology may aid decision-making by policy makers, especially in times of
economic difficulty, by showing which medication is more efficient.
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OBJECTIVES:BUCCOLAM (oromucosal midazolam) is approved for the treatment of
prolonged, acute, convulsive seizures in children and was the first product to re-
ceive a Paediatric-Use Marketing Authorisation (PUMA) in September 2011. The
product label includes use by parents and other carers such as teachers. Current
care in Germany for first line treatment consists mainly of rectal diazepam with
some use of buccal lorazepam, clonazepam and chloral hydrate. Some non-family
carers can be reluctant to administer these products due to concerns about social
acceptability, dignity or labelling issues. A decision tree model has been developed
to assess the cost of BUCCOLAM compared to current care for prolonged acute
convulsive seizures initially occurring in the community setting. METHODS: The
model evaluates costs along the treatment pathway when a child has a seizure
including whether or not carers administer treatment, whether an ambulance is
required and whether or not patients are taken to hospital and require an inpatient
stay. Data were obtained from a variety of sources including clinical effectiveness
estimates from McIntyre et al. 2005, and a Delphi panel. Costs were taken from
published sources. Estimates of the total eligible population were taken from epi-
lepsy prevalence data and the Delphi panel. RESULTS: Over one year, compared to
the mix of treatments representing current care, BUCCOLAM showed a reduction
in per patient costs of €3,469. Compared to treatment with rectal diazepam alone,
the most commonly used treatment, BUCCOLAM showed a cost reduction of
€3,533. It was expected that36,000 patients would be eligible. At an uptake of 20%
BUCCOLAM would reduce health care expenditure by €19.4 million in the first year.
CONCLUSIONS: Treatment with BUCCOLAM is cost-saving compared to current
care and treatment with rectal diazepam through a reduction in the need for am-
bulance call-outs and hospital stays.
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OBJECTIVES: Epilepsy is one of the most common chronic neurological disorders in
the world; therefore it is associated with substantial use of medical resources in
health institutions. Approximately 60% of patients with epilepsy suffer from par-
tial-onset seizures (POS), and among these, an estimated 30% have refractory dis-
ease. The objective of this study was to analyze the cost-effectiveness of lacos-
amide (LCM), a newer anti-epileptic drug (AED), versus second generation AEDs in
patients with refractory POS. METHODS: We conducted an economic evaluation,
using lamotrigine (LTG) 300 mg/day and topiramate (TPM) 200 mg/day as compar-
ators for LCM 200 and 400 mg/day. The perspective was the Mexican Social Security
Institute, in accordance with Mexican guidelines for Economic Evaluations. The
model included the cost of drug acquisition and management of adverse events
(AE) during the titration and 12 weeks of maintenance. Resource use associated
with AEs was defined according to the information gathered in a Delphi Panel. The
efficacy measure was the50% responder rate; i.e., the percentage of patients who
showed a 50% decrease in seizure frequency from baseline. An indirect compar-
ison was made. RESULTS: The adjusted response rates were 33% for LCM 200
mg/day (34% unadjusted), 39% LCM 400 mg/day (41% unadjusted), 24% for LTG (20%
unadjusted) and 31% for TPM (27% unadjusted). Costs per patient considering the
adjustment was MX$6,872, $7,836, $6,954 and $6,485 for LCM 200 mg, LCM 400 mg,
LTG and TPM, respectively. The cost per responder was lower for LCM 200 and 400
mg/day ($20,825 and $20,093, respectively) than TPM and LTG ($20,918 and $28,974,
respectively). Considering unadjusted data, LCM 200 and 400 mg/day had greater
differential in costs per responder compared with TPM or LTG. CONCLUSIONS:
From a Mexican perspective, lacosamide represents a cost-effective treatment op-
tion for patients with POS. Sponsored by UCB.
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OBJECTIVES: Controlled trials have found therapeutic plasma exchange (TPE) and
intravenous immunoglobulin (IVIg) infusion therapy to be equally efficacious in
treating Guillain-Barré syndrome (GBS). Due to increases in the price of IVIg com-
pared to human serum albumin (HSA), used as a replacement fluid in TPE, direct
hospital-level expenditures for TPE and IVIg for meaningful cost-differences be-
tween these treatments were exemined for Turkey. METHODS: Cost were calcu-
lated with Hacettepe University Hospital procedures for one cycle IVIg and TPE.
One cycle were defined for IVIg and TPE as 5 days and 5 series, respectively. A model
was developed which allows hospitals to input cost and reimbursement amounts
for both IVIg and TPE with HSA that results in real-time valuations of these inter-
ventions. Reimbursement amounts were obtained from publicly available Social
Security Institution (SGK) data resources to determine payment rates for TPE and
IVIg. Only direct cost and payer perspective were used for the calculation.
RESULTS: The direct cost of IVIg infusion sessions totaling 140,0 grams for 5 days
was 18,841 TL compared to a series of five TPE procedures, which had direct costs of
6,529 TL.CONCLUSIONS: In GBS patients, direct costs of IVIg therapy are more than
twice that of TPE. Given equivalent efficacy and similar severity and frequencies of
adverse events, TPE appears to be a less expensive first-line therapy option for
treatment of patients with GBS for Turkey.
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OBJECTIVES: To collate the published evidence evaluating economic burden of
co-morbidities in patients with Parkinson’s disease (PD) in Germany. METHODS: A
systematic search of electronic literature databases (Embase® and MEDLINE®) was
conducted from January 2001 to June 2012 to identify economic studies in English
evaluating co-morbidities in patients with PD in Germany. RESULTS: Four studies
of the 267 citations retrieved met the pre-defined inclusion criteria. During 2000-
2002, direct costs were higher in patients with dyskinesias and/or motor fluctua-
tions (€3300 [€4630]) or dementia (€3110 [€5610]) than patients without motor com-
plications (€1450 [€3760]) or dementia (€1530 [3460]). However, indirect costs were
higher for patients without dementia (€3780 [€6870]) than patients with dementia
(€1080 [€4110]). In 2006, daily total costs and PD drug treatment costs decreased
significantly in patients with dementia (€7.3 [7.3]; p0.05) and depression (€6.6 [5.8];
p0.05) than patients without dementia (€9.3 [13.9]) and depression (€7.6 [6.8]),
respectively. The decrease in the costs observed across patients presenting with
these co-morbidities may be attributed to the inadequate treatment of depression
or dementia among patients with PD. In 2009, direct costs demonstrated a signifi-
cant increase in patients with dyskinesia (€16,544 vs. €11,322; p0.003), dementia
(€21,142 vs. €10,619; p0.001), depression (€15,904 vs. €8826; p0.001), or psychosis
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